Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adherium Taps Nektar’s Former BD Exec To Head New North America Unit

This article was originally published in Clinica

Executive Summary

Adherium, the developer of the SmartInhaler technology for improving medication adherence in patients with chronic respiratory disorders, has appointed James Hattersley senior vice-president of business development, North America. Hattersley joins from US pharm firm Nektar Therapeutics, where he held a similar position. He will leverage his experience in identifying opportunities for commercial partnerships and strategic alliances to expand Adherium’s presence in the US and Canada. His appointment coincides with the opening of the company’s new San Francisco, California subsidiary serving that region, Adherium North America, Inc. Australian Stock Exchange-listed Adherium’s Smartinhaler platform comprises a range of approved Smartinhaler medication sensors which attach to prescription inhalers, and the SmartinhalerLive software, which integrates the data from the Smartinhalers into a usable form via communications protocols, mobile applications and cloud based software. The company teams up with pharma players, an example being AstraZeneca, with whom Adherium entered a long-term partnership last year to supply new devices and sensors to incorporate within global patient support programs for patients with COPD and asthma.

You may also be interested in...



Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Roche Dx' EMEA Head To Take Charge After Diggelmann Departs

Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.

Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio

Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.

Topics

UsernamePublicRestriction

Register

MT103298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel